12.12.22
A Terminalia arjuna extract was evidenced in a recent human clinical study to offer potential cardiovascular endurance benefits in a diverse population, in a study appearing in the Journal of Multidisciplinary Healthcare.
The ingredient, branded by Enovate Biolife as Oxyjun, was administered to half of a population of 72 adults between the ages of 30 and 70 years for eight weeks, while the other half of the population received a placebo.
The participants in the experimental group received 400 mg of the botanical extract for eight weeks, and researchers investigated several parameters of myocardial pumping capacity, with other secondary markers such as diastolic filling ratio, rate pressure product, and fatigue severity scale. Several safety parameters were also assessed.
The ingredient increased left ventricular ejection fraction (LVEF) by 6.28%, while the placebo group only experienced a 0.24% increase. Higher LVEF percentages signifies a stronger heartbeat, which is associated with better cardiovascular endurance. Additionally, studies show that LVEF decreases by 1% for every decade increase in biological age, and reductions in LVEF may affect heart health and increase feelings of fatigue and exertion during physical activity.
Additionally, those who took the placebo saw a reduction of 22.25% on the fatigue severity scale compared to baseline, a 1.54% reduction in RPP, and a 5.9% reduction in GGT levels (an established marker of endothelial function) from baseline, all of which signified improvements in cardiovascular fitness.
Previous studies evaluating arjuna extracts were primarily conducted in patients with chronic heart conditions, the authors noted, but this study is among the first to evaluate outcomes in a healthy population, aside from a prior study which had a population of ten healthy individuals.
In conclusion, the authors described the ingredient as “a potential cardio-protective option for aging and exercising adults who want to enhance their cardiac performance, per se, and during exercise.”
“The product, at a dose of 400 mg/ once a day, helps decrease fatigue without any adverse effects,” they wrote.
The ingredient, branded by Enovate Biolife as Oxyjun, was administered to half of a population of 72 adults between the ages of 30 and 70 years for eight weeks, while the other half of the population received a placebo.
The participants in the experimental group received 400 mg of the botanical extract for eight weeks, and researchers investigated several parameters of myocardial pumping capacity, with other secondary markers such as diastolic filling ratio, rate pressure product, and fatigue severity scale. Several safety parameters were also assessed.
The ingredient increased left ventricular ejection fraction (LVEF) by 6.28%, while the placebo group only experienced a 0.24% increase. Higher LVEF percentages signifies a stronger heartbeat, which is associated with better cardiovascular endurance. Additionally, studies show that LVEF decreases by 1% for every decade increase in biological age, and reductions in LVEF may affect heart health and increase feelings of fatigue and exertion during physical activity.
Additionally, those who took the placebo saw a reduction of 22.25% on the fatigue severity scale compared to baseline, a 1.54% reduction in RPP, and a 5.9% reduction in GGT levels (an established marker of endothelial function) from baseline, all of which signified improvements in cardiovascular fitness.
Previous studies evaluating arjuna extracts were primarily conducted in patients with chronic heart conditions, the authors noted, but this study is among the first to evaluate outcomes in a healthy population, aside from a prior study which had a population of ten healthy individuals.
In conclusion, the authors described the ingredient as “a potential cardio-protective option for aging and exercising adults who want to enhance their cardiac performance, per se, and during exercise.”
“The product, at a dose of 400 mg/ once a day, helps decrease fatigue without any adverse effects,” they wrote.
